Dr. Yanagiya from ARCALIS, Inc.’s business development department will present a poster at TIDES Asia, Oligonucleotide & Peptide Therapeutics which will be held from February 24^th (Tue) to 26^th (Thu), 2026, at the GRAND NIKKO TOKYO DAIBA. We cordially invite all conference participants to visit the poster.

【Event details】
Official website:   TIDES Asia: Oligonucleotide & Peptide Therapeutics
Date:  February 24^th (Wed) -26^th (Thu), 2026
Venue: GRAND NIKKO TOKYO DAIBA
Access: https://www.tokyo.grandnikko.com/eng/

【Poster presentation】
Title:  ARCALIS: An Integrated CDMO Empowering the Future of mRNA-based Therapeutics from Design to Manufacturing
Presenter: Dr. Akiko Yanagiya

【Abstract】
ARCALIS, Inc. is a CDMO specializing in the manufacturing of mRNA‑based therapeutics, vaccines for infectious diseases and cancer, along with additional therapeutic areas. We provide fully integrated services from mRNA design through large‑scale GMP manufacturing to ensure seamless development for our customers. In this presentation, we introduce four proprietary technologies developed to advance the creation of safe and effective mRNA-based therapeutics: (1) An organ‑selective mRNA delivery platform using optimized lipid compositions, (2) Our original saRNA platform enabling efficient and sustained protein expression, (3) An innovative codon optimization method based on mRNA stability prediction model by machine learning, named HARNA^TM, developed in collaboration with Hitachi, Inc., and (4) The utilization of T7 RNA polymerase to minimize dsRNA impurities and reduce undesirable immune response. These technologies enable the production of more efficient and safer mRNA therapeutics.